Do mRNA vaccines impact Cosentyx's effectiveness?
There is limited research specifically focusing on the interaction between mRNA vaccines and biologics like Cosentyx [1]. Cosentyx is an IL-17 inhibitor used to treat psoriasis, psoriatic arthritis, and ankylosing spondylitis. mRNA vaccines, such as those used in COVID-19 vaccines like Pfizer-BioNTech and Moderna, work by introducing a small piece of genetic material that instructs cells to produce a piece of a protein, which in turn triggers an immune response.
Comparing mRNA vaccines to Cosentyx: What are the differences in mechanism of action?
Keytruda (pembrolizumab), an immunotherapy drug used to treat various cancers, has been studied extensively in combination with COVID-19 vaccines [2]. However, studies investigating the interaction between mRNA vaccines and IL-17 inhibitors like Cosentyx are scarce.
Current studies on Cosentyx and mRNA vaccines: What's the current state of knowledge?
One pilot study on patients with moderate to severe psoriasis treated with Cosentyx found no significant difference in treatment response after administration of the Pfizer-BioNTech COVID-19 vaccine [3]. However, more research is needed to fully understand the potential impact of mRNA vaccines on Cosentyx's effectiveness.
When will we have more information about the interaction between MRNA vaccine and Cosentyx?
Future studies will hopefully provide more insights into the effects of mRNA vaccines on biologic therapies like Cosentyx. Patients undergoing or considering treatment with Cosentyx and mRNA vaccines should consult with their healthcare provider to discuss the best treatment plan.
Sources:
[1] - DrugPatentWatch.com
[2] - National Institute of Health (NIH) - ClinicalTrials.gov
[3] - European Journal of Dermatology, 2022